Other Issues:
|
Contents: September 2010, Volume 2010, Molecular Diagnostics Meeting
[Index by Author]
 High throughput technologies for marker discovery and validation |
| Functional and molecular imaging in vivo and in vitro |
| Nanotechnology approaches to molecular marker identification and validation |
| Molecular classification, predictive, and prognostic markers including cancer stem cells |
| Basic research, epigenetics, immunology, non-coding RNAs, tumor microenvironment, metastasis, target identification, validation, lead discovery, and optimization |
| Minimally invasive markers, circulating tumor cells, and plasma DNA and protein |
| Pharmacodynamics, pharmacokinetics, and pharmacogenomics |
| Molecular marker driven clinical trial design and implementation |
| Other Molecular Diagnostics Studies |
| Nanotechnology approaches to molecular marker identification and validation |
| High throughput technologies for marker discovery and validation |
| Nanotechnology approaches to molecular marker identification and validation |
| Molecular marker driven clinical trial design and implementation |
| Functional and molecular imaging in vivo and in vitro |
| Molecular classification, predictive, and prognostic markers including cancer stem cells |
| Pharmacodynamics, pharmacokinetics, and pharmacogenomics |
| Identification and validation of biomarkers |
| High throughput technologies for marker discovery and validation |
| Minimally invasive markers, circulating tumor cells, and plasma DNA and protein |
| Basic research, epigenetics, immunology, non-coding RNAs, tumor microenvironment, metastasis, target identification, validation, lead discovery, and optimization |
| High throughput technologies for marker discovery and validation |
| Pharmacodynamics, pharmacokinetics, and pharmacogenomics |
| Hurdles to molecular diagnostics development and implementation |
| Molecular prediction, classification, and prognostic markers |
| Molecular classification, predictive, and prognostic markers including cancer stem cells |
| Pharmacodynamics, pharmacokinetics, and pharmacogenomics |
| Functional and molecular imaging in vivo and in vitro |
| Basic research, epigenetics, immunology, non-coding RNAs, tumor microenvironment, metastasis, target identification, validation, lead discovery, and optimization |
| Molecular classification, predictive, and prognostic markers including cancer stem cells |
| Molecular marker driven clinical trial design and implementation |
| Molecular classification, predictive, and prognostic markers including cancer stem cells |
| High throughput technologies for marker discovery and validation |
| Other Molecular Diagnostics Studies |
| Molecular classification, predictive, and prognostic markers including cancer stem cells |
| Nanotechnology approaches to molecular marker identification and validation |
| Minimally invasive markers, circulating tumor cells, and plasma DNA and protein |
| Molecular classification, predictive, and prognostic markers including cancer stem cells |
| Other Molecular Diagnostics Studies |
| Molecular classification, predictive, and prognostic markers including cancer stem cells |
|
